Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ruthenium Compounds Differentially Inhibit Group IA and IIA Snake Venom Phospholipase A<sub>2</sub> Anticoagulant Activity.

International journal of molecular sciencesĀ·2026
Same author

DOACs, Andexanet, Pump Clots-Oh My! A Joint Consensus Statement for Safe Management of Patients on DOACs Requiring Cardiac Surgery.

Anesthesia and analgesiaĀ·2026
Same author

Procoagulant Effects of <i>Bothrops diporus</i> Venom: Kinetic Modeling and Role of Serine Protease Activity.

International journal of molecular sciencesĀ·2025
Same author

Special Issue "Advances in Coagulation and Anticoagulation".

International journal of molecular sciencesĀ·2025
Same author

Carbon Monoxide or Ruthenium: Will the Real Modulator of Coagulation and Fibrinolysis Please Stand Up!

International journal of molecular sciencesĀ·2025
Same author

Rattlesnake Roundup: Point-of-Care Thrombelastographic Methods Define the Molecular Impacts on Coagulation of <i>Crotalus</i> Venom Toxins In Vitro and In Vivo.

ToxinsĀ·2025

Related Experiment Video

Updated: May 30, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Redox-based thrombelastographic method to detect carboxyhemefibrinogen-mediated hypercoagulability.

Vance G Nielsen1, Matthew R Arkebauer, Keith Vosseller

  • 1Department of Anesthesiology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. vance.nielsen@drexelmed.edu

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|August 9, 2011
PubMed
Summary

Carbon monoxide in cigarette smoke increases blood clot strength by forming carboxyhemefibrinogen. A new redox method using phenylhydroxylamine (PHA) can reverse this effect, suggesting a way to measure smoking-induced hypercoagulability.

More Related Videos

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Related Experiment Videos

Last Updated: May 30, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Area of Science:

  • Biochemistry
  • Hematology
  • Toxicology

Background:

  • Cigarette smoking is linked to hypercoagulability, a state of increased blood clotting.
  • Carbon monoxide (CO) from smoking enhances coagulation by binding to heme in fibrinogen.
  • The resulting carboxyhemefibrinogen's role in hypercoagulability requires further investigation.

Purpose of the Study:

  • To develop and validate a redox-based assay for detecting carboxyhemefibrinogen.
  • To investigate the impact of CO on plasma coagulation and its modulation by a reductant.
  • To establish a mechanistic link between carboxyhemefibrinogen and in-vitro hypercoagulability.

Main Methods:

  • Pooled plasma was treated with a CO-releasing molecule (CORM-2) and/or phenylhydroxylamine (PHA).
  • PHA converts heme iron from Fe(+2) to Fe(+3), oxidizing carboxyhemefibrinogen to methemefibrinogen.
  • Thrombelastography measured clot strength (elastic modulus, G) after calcium and tissue factor activation.

Main Results:

  • CORM-2 significantly increased plasma clot strength (G) by 67.8%.
  • PHA pretreatment significantly reduced CORM-2-induced increases in G.
  • Conversion to methemefibrinogen alone decreased G, and PHA abrogated CO-mediated hypercoagulability.

Conclusions:

  • A redox-based method effectively detects carboxyhemefibrinogen formation.
  • Conversion of carboxyhemefibrinogen to methemefibrinogen reverses CO-induced hypercoagulability.
  • This assay could mechanistically link smoking, carboxyhemefibrinogen, and hypercoagulability in clinical studies.